Resultats de la cerca - Mor Moskovitz

  • Mostrar 1 - 10 resultats de 10
Refinar resultats
  1. 1
    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da... per Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung per Elizabeth Dudnik, Samuel A. Kareff, Mor Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

    Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome per Gil Bar‐Sela, Idan Cohen, Salvatore Campisi‐Pinto, Gil M. Lewitus, Lanuel Oz-Ari, Ayellet Jehassi, Avivit Peer, Ilit Turgeman, Olga Vernicova, Paula Berman, Mira Wollner, Mor Moskovitz, David Meiri

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors per Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

    Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial per Solange Peters, Shirish M. Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kılıçkap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao‐Hua Chiu, Chong‐Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael S. Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe J. Assaf, V.R. Archer, Rafał Dziadziuszko

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) per Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Pravin Patel, Hadas Gantz-Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian J. Hochmair, Kristof Cuppens, Lynn Decoster, Martin Reck, Dror Limon, Estelamari Rodríguez, Christoforos Astaras, Adrienne Bettini, Simon Häfliger, Alfredo Addeo

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R per Andrea Riccardo Filippi, Jair Bar, C. Chouaid, Daniel C. Christoph, John K. Field, R. Fietkau, M.C. Garassino, Pilar Garrido, Vilde Drageset Haakensen, Steven Kao, B. Markman, F. McDonald, F. Mornex, Mor Moskovitz, S. Peters, Anne Sibille, Shankar Siva, M. van den Heuvel, Piet Vercauter, S. Anand, P. Chander, M. Licour, A.R. de Lima, Y. Qiao, Noémie Girard

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non–Small Cell Lung Cancer in the Phase... per D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor‐Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

    Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer per Petros Christopoulos, Michal Harel, Kimberly McGregor, Yehuda Brody, Igor Puzanov, Jair Bar, Yehonatan Elon, Itamar Sela, Ben Yellin, Coren Lahav, Shani Raveh, Anat Reiner‐Benaim, Niels Reinmuth, Hovav Nechushtan, David Farrugia, Ernesto Bustinza-Linares, Yanyan Lou, Raya Leibowitz‐Amit, Iris Kamer, Alona Zer, Mor Moskovitz, Adva Levy‐Barda, Ina Koch, Michal Lotem, Rivka Katzenelson, Abed Agbarya, Gillian Price, Helen Cheley, Mahmoud Abu-Amna, T. Geldart, Maya Gottfried, Ella Tepper, Andreas Polychronis, Ido Wolf, Adam P. Dicker, David P. Carbone, David R. Gandara

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial per Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian J. Hochmair, Mark M. Awad, Michael Thomas, Glenwood Goss, Paul Wheatley‐Price, Frances A. Shepherd, Marie Florescu, Parneet Cheema, Quincy Chu, Sang‐We Kim, Daniel Morgensztern, Melissa L. Johnson, Sophie Cousin, Dong‐Wan Kim, Mor Moskovitz, David Vicente, Boaz E. Aronson, Rosalind Hobson, Helen J. Ambrose, Sajan Khosla, Avinash Reddy, Deanna L. Russell, Mohamed Reda Keddar, James Conway, J. Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J. Jewsbury, Sonia Iyer, Simon T. Barry, Jan Cosaert, John V. Heymach

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: